NovaBay Pharmaceuticals, Inc. (NBY) is a publicly traded Healthcare sector company. As of May 21, 2026, NBY trades at $1.95 with a market cap of $51.92M and a P/E ratio of 0.12. NBY moved +23.42% today. Year to date, NBY is -62.14%; over the trailing twelve months it is -31.82%. Its 52-week range spans $1.11 to $99.75. Analyst consensus is hold with an average price target of $0.00. Rallies surfaces NBY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NBY financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NBY recently traded at $1.95. Market cap is $51.92M. P/E ratio is 0.12. Revenue is $2.46M.
| Metric | Value |
|---|---|
| Price | $1.95 |
| Market Cap | $51.92M |
| P/E Ratio | 0.12 |
| EPS | $16.10 |
| Dividend Yield | 0.80% |
| 52-Week High | $99.75 |
| 52-Week Low | $1.11 |
| Volume | 637.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.46M |
| Net Income | $522.59M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-22.14M | $-3.80 |
| 2024 | $9.78M | $-7.33M | $-2.53 |
| 2023 | $14.73M | $-9.64M | $-3.96 |
| 2022 | $14.40M | $-10.61M | $-10.10 |
5 analysts cover NBY: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $0.00.